Brincidofovir (1 brand name, 2 dosage forms, 1 route)
Available dosage forms: TABLET, SUSPENSION.
Routes of administration: ORAL.
Brand Names
- TEMBEXA
Boxed Warning
An increased incidence of mortality was seen in TEMBEXA-treated subjects compared to placebo-treated subjects in a 24-week clinical trial when TEMBEXA was evaluated in another disease [see Warnings and Precautions (5.1)].
Contraindications
None.
Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: •Elevations in hepatic transaminases and bilirubin [see Warnings and Precautions (5.2)] •Diarrhea and other GI adverse events [see Warnings and Precautions (5.3)]
Mechanism of Action
Brincidofovir is an antiviral drug against variola (smallpox) virus [see Microbiology (12.4)].
Overdosage
There is no clinical experience with overdosage of TEMBEXA. In the event of an overdose, monitor patients for adverse effects and provide appropriate supportive care.